Navigation Links
Clear racial discrepancies exist among patients with CKD

Washington, DC (May 19, 2008) Black patients have a higher risk of dying in the early stages of chronic kidney disease (CKD) than whites, according to a study appearing in the July 2008 issue of the Journal of the American Society Nephrology (JASN). The findings may explain why blacks have better survival rates once they reach advanced stages of the diseasein essence, because only the healthiest blacks are surviving long enough to develop later stages of the disease. If white patients are given better care in managing their condition early on, even less healthy patients may live to develop advanced disease. But, their compromised health may put them at increased risk of death in the long term compared with blacks.

In addition, the studys results indicate that racial differences in the death rates of chronic kidney disease patients depend more on sociological factors than on biological ones. Poverty and lack of education and medical insurance in particular may contribute to the high death rates among black individuals.

Previous research has documented that, in general, mortality rates for black individuals are persistently higher than those for whites. However, among patients with late-stage chronic kidney disease, the trend is reversed and black individuals have a survival advantage over whites. Hispanic patients also seem to have a survival advantage over whites in these situations.

Puzzled by this paradox, Dr. Rajnish Mehrotra of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and colleagues set out to find an explanation. They assessed data from a total of 14,611 patients in the Third National Health and Nutrition Examination Survey (NHANESIII), a population-based survey of community-dwelling individuals.

The investigators found that 2,892 of the individuals in the survey had chronic kidney disease, 1,127 of whom died during follow-up. Among those with early-stage disease who were younger than 65 years, blacks had a 78% higher risk of death compared with whites. This elevated risk was significantly related to socioeconomic status and access-to-care. There was also a nonsignificant trend for higher mortality among Hispanics compared with whites.

Dr. Mehrotra and his team conclude that their findings may explain the lower mortality rates observed among black individuals with advanced kidney disease. Blacks may not be receiving as high a quality of care as whites during the early stages of their disease, so that only healthier blacks are surviving and developing later stages of chronic kidney disease.

These data suggest that factors such as education, poverty, and lower probability of medical insurance may be more important in mediating the high risk for death among younger black individuals than are biologic differences, the authors write. This, in turn, may help in prioritizing interventions aimed at reducing the disparities among younger black individuals with chronic kidney disease.


Contact: Shari Leventhal
American Society of Nephrology

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Nurses Send Sutter a Clear Message
3. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
4. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
5. Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women
6. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
7. Trade-offs reveal no clear favorites in alternative energy market
8. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
9. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
10. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
11. NDO Receives FDA 510(K) Clearance for Plicator II(TM)
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Los Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... advanced da Vinci surgical robot is being more and more widely heralded as a ... robotic assisted da Vinci method has over traditional laparoscopic surgery is that it can ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: